New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear

Journal of Clinical Epidemiology

Volumn 61, Issue 3, 2008, Pages 301-307

  Boissel, Jean Pierre ^a   Cucherat, Michel ^b   Nony, Patrice ^c   Chabaud, Sylvie ^d   Gueyffier, François ^e   Wright, James M ^f   Lièvre, Michel ^g   Leizorovicz, Alain ^a  

^a LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^b University Hospital of Lyon   (France)

^c Cardiovascular Hospital   (France)

^d Regional Anticancer Centre   (France)

^e INSERM   (France)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Absolute benefit; Curvilinear relation; Numerical modeling; Physiopathology; Relative risk; Simulation; Therapy effect model

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; DISEASE SEVERITY; HEALTH CARE POLICY; HUMAN; LINEAR SYSTEM; PRIORITY JOURNAL; RISK ASSESSMENT; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38549102038     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.07.007     Document Type: Article

References (23)

1. L'Abbe K.A., Detsky A.S., and O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 107 (1987) 224-233
2. Boissel J.P., Collet J.P., Lièvre M., and Girard P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in post-myocardial infarction patients. J Cardiovasc Pharmacol 22 (1993) 356-363
3. Hoes A.W., Grobbee D.E., and Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 13 (1995) 805-811
4. Sharp S.J., Thompson S.G., and Altman D.G. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 313 (1996) 735-738
5. Arends L.R., Hoes A.W., Lubsen J., Grobbee D.E., and Stijnen T. Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. Stat Med 19 (2000) 3497-3518
6. Stewart L.A., and Clarke M.J. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 14 (1995) 2057-2079
7. Yusuf S., Peto R., Lewis J.A., Collins R., and Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
8. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
9. Beta-Blocker Pooling Project Research Group (Coordinators: Boissel JP, Leizorovicz A). The Beta-blocker Pooling Project (B.B.P.P.): subgroup findings from randomized trials in post infarction patients. Eur Heart J 9 (1988) 8-16
10. McIntosh M.W. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 15 (1996) 1713-1728
11. Gueyffier F., Bulpitt C., Boissel J.P., Schron E., Ekbom T., Fagard R., et al., for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 353 (1999) 793-796
12. Boissel J.P., Gueyffier F., and Haugh M.C. Response to "Inclusion of women and minorities in clinical trials and the NIH revitalization act of 1993. The perspective of NIH clinical trialists". Control Clin Trials 16 (1995) 286-288
13. Boissel J.P., Gueyffier F., Cucherat M., and Bricca G. Pharmacogenetics and responders to a therapy: theoretical background and practical problems. Clin Chem Lab Med 41 (2003) 564-572
14. Chabaud S., Girard P., Nony P., Boissel J.P., and on behalf of the THERMOS group. Clinical trial simulation using therapeutic effect modelling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 29 (2002) 339-363
15. Nony P., Cucherat M., and Boissel J.P. Revisiting the effect compartment through timing errors in drug administration. TiPS 19 (1998) 49-54
16. Gabrielsson J., and Weiner D. Pharmacokinetic and pharmacodynamic data analysis (2000), Swedish Pharmaceutical Society, Stockholm p. 61
17. Duffull S.B., Chabaud S., Nony P., Laveille C., Girard P., and Aarons L. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 10 (2000) 285-294
18. Duffull S.B., and Aarons L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 10 (2000) 275-284
19. Laupacis A.L., Sackett D.L., and Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318 (1988) 1728-1733
20. Glasziou P.P., and Irwig L.M. An evidence based approach to individualising treatment. BMJ 311 (1995) 1356-1359
21. Boissel J.P. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA 280 (1998) 1949-1950
22. Senn S. Individual response to treatment: is it a valid assumption?. BMJ 329 (2004) 966-968
23. Boissel J.P., Leizorovicz A., Picolet H., Peyrieux J.C., and for the APSI Investigators. Secondary prevention after high-risk acute myocardial infarction with low-dose Acebutolol. Am J Cardiol 66 (1990) 251-260